Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer, renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
Adam M. Brufsky, MD, PhD
person default
Cristina Saura, MD, PhD

On-Demand Webcast

In this interactive, on-demand Webcast, experts share recent developments in the care of patients with HER2-positive metastatic breast cancer, including novel therapeutic agents and strategies utilizing new antibody–drug conjugates and tyrosine kinase inhibitors after failure of standard-of-care treatments.

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

ClinicalThought

How confident are you in managing patients who experience interstitial lung disease while receiving trastuzumab deruxtecan?

Adam M. Brufsky, MD, PhD Released: September 10, 2020

Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.

person default Cristina Saura, MD, PhD Released: September 11, 2020

Downloadable Slidesets

Download this slideset on the new and emerging antibody drug conjugates for HER2-postive MBC.

Adam M. Brufsky, MD, PhD Released: May 29, 2020

Download this slideset on newer TKIs for relapsed or refractory HER2-positive metastatic breast cancer.

person default Cristina Saura, MD, PhD Released: May 29, 2020

Download this slideset covering a novel HER2-targeted antibody and case discussions for managing progressive HER2-positive MBC with new therapies.

Thomas Bachelot, MD, PhD Released: May 29, 2020

Download this short summary slideset of key takeaway points from a live presentation on the novel therapies for relapsed or refractory HER2-postivie metastatic breast cancer.

Thomas Bachelot, MD, PhD Adam M. Brufsky, MD, PhD person default Cristina Saura, MD, PhD Released: May 29, 2020

Podcast

Listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss 2 real-world cases of patients with HER2-positive MBC and clinical considerations in the evolving state-of-the-art care treatment landscape.

Thomas Bachelot, MD, PhD Adam M. Brufsky, MD, PhD person default Cristina Saura, MD, PhD Released: September 21, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue